CD274 and lung carcinoma: This notion is especially highlighted by the fact that the clinical trial in patients with advanced lung cancer involving PD-L1–CAR T cells (ClinicalTrials.gov Identifier: NCT03330834) was recently terminated due to serious, however, resolved on tocilizumab and steroids treatment, adverse effects after one patient received the treatment.